EXPERIMENTAL INTRAOPERATIVE RADIOTHERAPY

总体目标是提供关于类型和概率的信息 术中照射造成的正常组织损伤， 常规辐照方案。 术中治疗的兴趣 由于难以提供足够的辐射剂量， 肿瘤位于重要的放射敏感器官或组织附近。 肿瘤 邻近或包括主要血管的血管难以切除 彻底 本研究的目的是确定早期和晚期反应 犬主动脉旁组织单独接受大剂量辐射， 在分次外部束照射之后。 顺序检查 将包括动脉造影、静脉尿路造影、血液和尿液 化学，周围神经损伤的观察， 电生理测量。 第2年和第5年的尸检将提供 用于周围神经、肌肉、大 血管和其他主动脉旁结构。 特别令人感兴趣的是 薄壁组织、基质和微血管的体积变化百分比。 的 将组织学分析与连续功能研究进行比较。 将比较每种类型的参数的等效剂量。 剂量输送，以确定各种相对有效性的大 术中单独或联合给予单次放射剂量 分次放射及其剂量 一个人 这些决定尚未完成，但对那些 开展人类临床试验，以帮助判断相对风险， 对不可切除或局部晚期癌症患者的潜在获益。

The overall objective is to provide information on the type and probability of normal tissue damage from intraoperative irradiation as compared to more conventional irradiation protocols. The interest in intraoperative therapy was stimulated because of difficulty in delivering adequate radiation doses to tumors located near critical radiosensitive organs or tissues. Tumors adjacent to or including major blood vessels are difficult to excise completely. The aim of this study is to determine early and late response of canine paraaortic tissues to large single doses of radiation alone and following fractionated external beam irradiation. Sequential examinations will include arteriograms, intravenous urography, blood and urine chemistries, observations for peripheral nerve injury and electrophysiologic measurements. Necropsies at 2 and 5 years will provide tissues for morphometric analysis of peripheral nerves, muscles, great vessels and other paraaortic structure. Of particular interest will be the percentage volume changes in perenchyma, stroma and microvasculature. The histologic analyses will be compared to the sequential functional studies. The isoeffective doses will be compared for parameters for each type of dose delivery to determine the various relative effectiveness of large single radiation doses delivered intraoperatively alone or combined with fractionated radiation with the dose delivered by fractionated radiation alone. Those determinations have not been done but are essential to those developing human clinical trials to aid in judging the relative risk and potential benefit to patients with nonresectable or locally advanced cancer.